{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.98","value":"1.8"},{"groupId":"OG001","spread":"20.31","value":"-7.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"305"},{"groupId":"OG001","value":"100"}],"units":"Participants"}],"title":"Cycle 2, Week 1, Day 1 change from BL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.82","value":"1.4"},{"groupId":"OG001","spread":"21.50","value":"-3.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"272"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"title":"Cycle 3, Week 1, Day 1 change from BL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.18","value":"2.8"},{"groupId":"OG001","spread":"18.73","value":"-1.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"221"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"Cycle 4, Week 1, Day 1 change from BL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.30","value":"4.0"},{"groupId":"OG001","spread":"28.88","value":"-8.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"title":"Cycle 5, Week 1, Day 1 change from BL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.61","value":"2.1"},{"groupId":"OG001","spread":"19.43","value":"3.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Cycle 6, Week 1, Day 1 change from BL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.64","value":"3.6"},{"groupId":"OG001","spread":"12.79","value":"5.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Cycle 7, Week 1, Day 1 change from BL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.18","value":"0.6"},{"groupId":"OG001","spread":"16.60","value":"13.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"Cycle 8, Week 1, Day 1 change from BL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.68","value":"0.1"},{"groupId":"OG001","spread":"20.82","value":"6.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Cycle 9, Week 1, Day 1 change from BL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.97","value":"2.9"},{"groupId":"OG001","spread":"2.83","value":"-8.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Cycle 10, Week 1, Day 1 change from BL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.33","value":"5.8"},{"groupId":"OG001","spread":"28.28","value":"-9.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Cycle 11, Week 1, Day 1 change from BL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.03","value":"4.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Cycle 12, Week 1, Day 1 change from BL"},{"categories":[{"measurements":[{"comment":"NA: Only one participant analyzed","groupId":"OG000","spread":"NA","value":"-5.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Cycle 13, Week 1, Day 1 change from BL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.07","value":"-8.9"},{"groupId":"OG001","spread":"21.49","value":"-10.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"86"}],"units":"Participants"}],"title":"End of Treatment (EoT) change from BL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"196"}],"units":"Participants"}],"description":"The EQ-5D-5L is a standardized participant completed questionnaire that measures health-related quality of life. EQ-5D-5L consists of two components: a health state profile and an optional visual analogue scale (VAS). EQ VAS records the patient's self-rated health on a vertical visual analogue 0-100 scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The higher the EQ-VAS score, the better the QoL.","dispersionType":"Standard Deviation","groups":[{"description":"Patients randomized to receive the investigational product received 7.4 GBq (+/- 10%) 177Lu-PSMA-617 intravenously every 6 weeks (+/- 1 week) for a maximum of 6 cycles. Best supportive/best standard of care (BS/BSOC) might be used","id":"OG000","title":"Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)"},{"description":"Patients randomized to this arm received best supportive/best standard of care (BS/BSOC) as determined by the investigator","id":"OG001","title":"Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone"}],"paramType":"MEAN","populationDescription":"PFS Full Analysis Set (PFS-FAS). Only participants with non-missing score both at Baseline and at post-baseline visits were included in the analysis.","reportingStatus":"POSTED","timeFrame":"Baseline (BL), Cycle 2 to Cycle 13 (Week 1 Day 1), End of Treatment (EoT) (cycle duration for Cycle 1-6 = 6 weeks and for Cycle 7 and beyond = 12 weeks)","title":"Change From Baseline in the European Quality of Life (EuroQol) - 5 Domain 5 Level Scale (EQ-5D-5L) EQ-VAS","type":"SECONDARY","unitOfMeasure":"Score on a scale"}